
Opinion|Videos|October 21, 2024
Health Care Resource Utilization: Luspatercept vs ESAs in MDS
Author(s)Saeed Sadeghi, MD
Saeed Sadeghi, MD, discusses the impact of health care resource utilization on treatment decisions and quality of life for patients with myelodysplastic syndromes (MDS), highlighting real-world data presented at SOHO that compares the resource utilization of U.S. patients treated with luspatercept versus erythropoiesis-stimulating agents (ESAs).
Advertisement
Episodes in this series

Video content above is prompted by the following:
Health care resource utilization is an important factor in deciding on treatments and affects quality of life for patients.
- Please briefly discuss the real-world data presented at SOHO comparing the health resource utilization of US patients with MDS treated with luspatercept vs ESAs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5
















